SPDR S&P Pharmaceuticals ETF

Yield per half year: 0.3%
Industry: Health & Biotech Equities

Category	Share, %	Quantity
Healthcare	98.36342	44

Exchange	Share, %	Quantity
NASDAQ	68.18	30
New York Stock Exchange	31.82	14

Share by country

Country	Quantity	Companies
United States	41	Corcept Therapeutics Incorporated (share - 4.15%) Bristol-Myers (share - 3.73%) Zoetis (share - 3.64%) Catalent (share - 3.63%) PFIZER (share - 3.62%) Intra-Cellular Therapies, Inc. (share - 3.6%) Eli Lilly and Company (share - 3.6%) Royalty Pharma plc (share - 3.59%) Merck & Co (share - 3.57%) Johnson & Johnson (share - 3.53%) Viatris (share - 3.53%) Axsome Therapeutics, Inc. (share - 3.5%) Organon & Co. (share - 3.45%) Elanco Animal Health (share - 3.45%) Cassava Sciences, Inc. (share - 3.03%) Edgewise Therapeutics, Inc. (share - 2.81%) Arvinas, Inc. (share - 2.61%) Longboard Pharmaceuticals, Inc. (share - 2.35%) Prestige Consumer Healthcare Inc. (share - 2.23%) Amphastar Pharmaceuticals, Inc. (share - 2.22%) Tarsus Pharmaceuticals, Inc. (share - 2.07%) Collegium Pharmaceutical, Inc. (share - 1.93%) Supernus Pharmaceuticals, Inc. (share - 1.9%) Pacira BioSciences, Inc. (share - 1.73%) ANI Pharmaceuticals (share - 1.6%) Ligand Pharmaceuticals Incorporated (share - 1.59%) Harmony Biosciences Holdings, Inc. (share - 1.46%) Harrow Health, Inc. (share - 1.31%) Amneal Pharmaceuticals, Inc. (share - 1.3%) Ocular Therapeutix, Inc. (share - 1.3%) Innoviva, Inc. (share - 1%) Phathom Pharmaceuticals, Inc. (share - 0.9569%) Liquidia Corporation (share - 0.9387%) Mind Medicine (MindMed) Inc. (share - 0.9262%) Fulcrum Therapeutics, Inc. (share - 0.8511%) Pliant Therapeutics, Inc. (share - 0.7955%) EyePoint Pharmaceuticals, Inc. (share - 0.7819%) Evolus, Inc. (share - 0.7253%) Enliven Therapeutics, Inc. (share - 0.645%) Nuvation Bio Inc. (share - 0.5807%) Xeris Pharmaceuticals, Inc. (share - 0.4415%)
Ireland	2	Jazz Pharmaceuticals plc (share - 3.6%) Perrigo (share - 3.44%)
Singapore	1	Wave Life Sciences Ltd. (share - 0.6656%)

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

Subscribe